Quarterly report [Sections 13 or 15(d)]

Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.25.3
Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Segment Information    
Number of reportable segment not disclosed true  
Revenues, net $ 286,555 $ 289,458
Consolidated net sales 286,555 289,458
Cost of sales 98,443 106,441
Selling, general and administrative 116,213 119,161
Research and development 24,241 23,869
Operating income 47,658 39,987
Recovery of assets held-for-sale 6,789  
Operating Segments    
Segment Information    
Revenues, net 281,646 287,727
Operating income 86,591 84,818
Operating Segments | Protein Sciences    
Segment Information    
Revenues, net 202,188 204,535
Cost of sales 50,518 52,498
Selling, general and administrative 59,766 57,132
Research and development 14,191 14,364
Operating income 77,713 80,541
Operating Segments | Diagnostics and Spatial Biology    
Segment Information    
Revenues, net 79,458 83,192
Cost of sales 33,737 35,633
Selling, general and administrative 27,851 33,518
Research and development 8,992 9,764
Operating income 8,878 4,277
Operating Segments | Other revenue    
Segment Information    
Other revenues 5,439 2,303
Intersegment Eliminations    
Segment Information    
Revenues, net (530) (572)
Corporate, Non-Segment    
Segment Information    
Selling, general and administrative (2,433) (1,586)
Amortization of intangibles (15,350) (19,741)
Acquisition related expenses and other (3,351) (1,701)
Certain litigation charges (2,408) (292)
Stock based compensation, inclusive of employer taxes (12,096) (10,637)
Restructuring and restructuring-related costs (7,511) (11,022)
Recovery of assets held-for-sale 6,789  
Impact of business held-for-sale(1) $ (2,573) $ 148